AKBA Akebia Therapeutics Inc.

4.25
-0.02  -0%
Previous Close 4.27
Open 4.29
Price To Book 0.88
Market Cap 500,916,016
Shares 117,862,592
Volume 84,385
Short Ratio
Av. Daily Volume 1,152,816

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in 2019.
Vadadustat - TRILO2GY
Three-times-weekly dosing regimen for vadadustat
Phase 2 trial data due 2019.
Vadadustat - FO2RWARD
Renal anemia
Approved Sept 5, 2014.
Auryxia
Hyperphosphatemia
Phase 3 data due 2Q 2020.
Vadadustat - INNO2VATE
Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)
Phase 3 data due mid-2020.
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)
sNDA FDA Approval announced November 7, 2017.
Auryxia
Iron deficiency anemia in non-dialysis dependent CKD patients

Latest News

  1. Akebia Therapeutics CEO, John P. Butler, Elected Chair of Kidney Care Partners
  2. Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan
  3. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  4. When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
  5. Hedge Funds Are Dumping Akebia Therapeutics Inc (AKBA)
  6. Edited Transcript of AKBA earnings conference call or presentation 9-May-19 1:00pm GMT
  7. Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease
  8. Akebia Therapeutics to Participate in Upcoming Investor Conferences
  9. Akebia Therapeutics, Inc. (AKBA) Q1 2019 Earnings Call Transcript
  10. Here’s What Hedge Funds Think About Akebia Therapeutics Inc (AKBA)
  11. Akebia Therapeutics: 1Q Earnings Snapshot
  12. Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments
  13. Seth Klarman Keeps Buying This Biotech Stock
  14. Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know
  15. Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings
  16. Akebia Therapeutics to Report First Quarter 2019 Financial Results
  17. Akebia Expands Vadadustat Licensing Deal With Vifor Pharma